SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus expanding cancer-treatment pipeline, especially the FDA-cleared REGAIN glioblastoma trial and anticipated clinical updates; traders are also watching pancreatic-cancer progress and a possible Keytruda-combination IDE, which remains speculative. Sentiment is broadly bullish on the early data and upcoming milestones, while some note the shares have been consolidating near resistance and await stronger evidence from larger patient groups.

Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA.

Airbnb Inc - Ordinary Shares - Class A

Airbnb Inc

Airbnbs quarterly results beat expectations and the company raised its outlook, alongside a new share-repurchase authorization, driving a sharp, high-volume rally. Bulls welcomed accelerating bookings and growth, while skeptics questioned whether travel demand can hold up amid consumer pressures and pointed to valuation and margin concerns.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,805,873.7130931 in circulation. The last known price of Litecoin is 52.00804602 USD and is down -0.75 over the last 24 hours. It is currently trading on 1567 active market(s) with $117,565,973.29 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoin is drawing attention amid a pullback that has erased much of its earlier rally, with traders debating whether recent lows will hold or the decline will continue. Some are buying the dip and anticipating a rebound, while others point to LTCs repeated givebacks and ongoing underperformance.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Discussion centers on strong CARVYKTI sales and the upcoming Q3 results, with traders also watching for an LB2501 in-vivo CAR-T data update. Optimism about the pipeline and possible pharma dealmaking competes with skepticism over whether early clinical responses will prove durable; acquisition talk remains speculative.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

A broad S&P 500 selloff is driving attention to VOO, with traders split between calling the weakness a dip-buying opportunity and warning it could deepen into a bear market. The discussion points to several possible pressuresincluding higher rates and inflation, tech-sector weakness, and uncertainty around the Iran conflict and U.S. politicswithout a single agreed cause.

Worldcoin (WLD) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Worldcoin has a current supply of 10,000,000,000 with 3,745,446,079.43649 in circulation. The last known price of Worldcoin is 0.33180531 USD and is down -3.31 over the last 24 hours. It is currently trading on 594 active market(s) with $173,507,845.37 traded over the last 24 hours. More information can be found at https://worldcoin.org/.

Worldcoin

WLD is drawing attention amid a sharp pullback, with traders debating whether the decline is a buying opportunity or a sign the token is continuing to fade. Repeated claims of net buying have fueled rebound speculation, but bearish comments point to ongoing selling and weak momentum.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly report and reduced full-year sales outlook are driving attention: traders cite slower HOKA and UGG growth and cautious consumer demand despite an earnings beat, with tariff refunds boosting the profit outlook. The sharp selloff has split the community between buyers pointing to strong margins, cash, and buybacks and skeptics focused on weaker underlying growth.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,398,959.154897 in circulation. The last known price of Algorand is 0.09511009 USD and is down -1.88 over the last 24 hours. It is currently trading on 586 active market(s) with $50,888,027.03 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Algorand is drawing attention amid weak price action near recent lows, with traders citing bearish technical signals and continued underperformance while bullish holders frame the decline as accumulation ahead of a potential altcoin recovery. The discussion is sharply divided between calls for further downside and optimism around the new leadership and Algorands quantum-resistant and tokenization technology.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,109,371. The last known price of Bitcoin is 75,663.53857906 USD and is down -0.17 over the last 24 hours. It is currently trading on 12776 active market(s) with $9,277,191,640.33 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins persistent weakness and choppy trading near support have fueled debate over whether selling pressure will lead to a deeper decline or the range marks accumulation. Bears point to repeated resistance and liquidation risks, while bulls argue support is holding and expect a rebound.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,095,630.40630647. The last known price of Pepe is 0.00000482 USD and is down -3.26 over the last 24 hours. It is currently trading on 729 active market(s) with $184,124,733.67 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPEs choppy price action, with sharp rebounds repeatedly running into resistance, is the main focus. Bulls view its ability to bounce and sometimes hold up better than other crypto assets as a potential breakout setup, while skeptics point to failed rallies, weak volume, and broader market weakness.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone 

Equity

BofA said concerns about adoption of Axsome’s Alzheimer’s agitation treatment and its ability to meet full-year 2027 revenue estimates have weighed on shares.

AXSM Stock Hits Fresh 52-Week Lows As Launch Concerns Of Auvelity In Alzheimer's Care Outweigh Q3 Beat

Axsome reported total net product revenue of $259.7 million, up 52% from $171.0 million a year earlier, with Auvelity accounting for a majority of it. 


Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +63.77% and +5.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

Top 3 Health Care Stocks That Could Blast Off In October

Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.read more...

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

• Reported GAAP EPS of -$0.25 up 73.40% YoY
• Reported revenue of $259.69M up 51.87% YoY
• Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan; no quantified revenue, margin, or earnings guidance was provided.

Axsome reported increased SG&A expenses primarily reflecting AUVELITY and SYMBRAVO commercialization, cash and cash equivalents of $313.9M, and risks to product commercial success and payer coverage.

Axsome's AUVELITY prescriptions and sales increased, SYMBRAVO prescriptions and sales increased, and the SUMMIT Phase 3 trial of AXS-05 for smoking cessation began, with topline results anticipated in 2H 2027.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>BofA lowered its price target on Axsome to $264 from $276 but maintained a ‘Buy’ rating, representing an 85% upside potential.</li><li>TD Cowen analyst Joseph Thome reiterated a ‘Buy’ rating with a $135 price target, calling shares ‘significantly undervalued.’</li><li>Axsome reported a 52% surge in Q3 revenue to $259.7 million, above estimates of $249.2 million, according to Fiscal.ai</li></ul>Shares of Axsome Therapeutics (AXSM) have declined nearly 20% over the past month, but Wall Street believes the selloff may be excessive despite concerns surrounding the company’s Alzheimer's disease agitation treatment launch.<a class="mention" data-mention="$AXSM" data-symbol-id="AXSM" href="https://stocktwits.com/symbol/AXSM" target="_blank">AXSM stock</a> was up 5% at the time of writing, having fallen to a 52-week low in the previous session.<h2 class="st-heading-2">BofA Still Sees Significant Upside</h2>BofA lowered its price target on Axsome to $264 from $276 but maintained a ‘Buy’ rating, according to The Fly. The updated price target still implies a roughly 85% upside from current levels.The firm said that while Axsome’s third-quarter (Q3) results were largely in line with expectations, investors remain concerned about the pace of the Alzheimer’s agitation treatment launch and whether the company can meet full-year 2027 estimates.BofA said concerns about the slower-than-expected adoption of Axsome’s Alzheimer’s agitation treatment and its ability to meet full-year 2027 revenue estimates have weighed on shares, but the firm believes the selloff is excessive given the drug’s long-term growth potential.Meanwhile, Baird lowered its price target on Axsome to $220 from $246 and keeps an Outperform rating on the shares.&nbsp;<h2 class="st-heading-2">Axsome’s Q3 Revenue Growth Driven By Auvelity Sales</h2>Axsome <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/11/02/3392981/0/en/axsome-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html">reported</a> a 52% surge in third-quarter (Q3) revenue to $259.7 million, above estimates of $249.2 million, according to Fiscal.ai. Auvelity drove the growth, with sales up 53% to $207.6 million.The company reported a loss of $0.25 per share, beating consensus estimates of a $0.64 per-share loss. Axsome ended September with $313.9 million in cash and expects its existing funds to support operations until it becomes cash-flow positive.Auvelity, an oral medication, was originally approved in 2022 to treat major depressive disorder. In April, 2026, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia">approved</a> Auvelity for agitation associated with Alzheimer’s dementia. Axsome launched the treatment for this new use in June 2026.<h2 class="st-heading-2">Retail’s Take On AXSM</h2>Retail sentiment surrounding AXSM on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.AXSM shares are down nearly 20% year-to-date.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/organigram-swoops-in-to-acquire-aurora-cannabis-topping-curaleaf-bid/cNGXBmAR9dc">Organigram Swoops In To Acquire Aurora Cannabis, Topping Curaleaf’s Rival Bid – ACB Stock Surges To Over 10-Month Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of US biopharma company Axsome Therapeutics Inc. seen displayed on a smartphone in front of an abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.08	--	--	N/A
Q3 '26	-$0.63	-$0.25	60.58%	BEAT
Q2 '26	-$0.89	-$0.99	-10.98%	MISSED
Q1 '26	-$0.81	-$1.26	-54.69%	MISSED
Q4 '25	-$0.69	-$0.56	19.13%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXSM Earnings

Latest Earnings Results: Q3 '26

Historical Earnings